Opinion: ACA's taxes, fees threaten new drug development

02/5/2013 | Forbes

The Affordable Care Act is a threat to the development of new drugs because it is filled with new taxes and fees on the health care industry, Pacific Research Institute president and CEO Sally C. Pipes writes. Innovation requires patience, time and money, but the ACA has placed a $22 billion tax on innovative drugmakers and 2.3% tax on the sales of medical-device makers, Pipes writes. Pipes cites the Analysis Group report that found 5,400 new drugs are being developed, but the promise of the pipeline demands innovation, not government interference, Pipes writes.

View Full Article in:

Forbes